API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/03/12/2844430/0/en/Pliant-Therapeutics-Announces-Accelerated-Bexotegrast-Development-Plan-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html
https://www.globenewswire.com//news-release/2023/11/13/2779524/0/en/Pliant-Therapeutics-Presentations-at-The-Liver-Meeting-2023-Highlight-Bexotegrast-an-Inhibitor-of-%CE%B1v%C3%9F6-and-%CE%B1v%C3%9F1-Integrins-in-Primary-Sclerosing-Cholangitis.html
https://www.globenewswire.com//news-release/2023/10/19/2763114/0/en/Pliant-Therapeutics-INTEGRIS-PSC-Phase-2a-Interim-Data-Evaluating-Bexotegrast-in-Primary-Sclerosing-Cholangitis-to-be-Highlighted-in-an-Oral-Late-Breaking-Presentation-at-The-Liver.html
https://www.globenewswire.com//news-release/2023/09/26/2749368/0/en/Pliant-Therapeutics-Announces-Positive-Safety-and-Exploratory-Efficacy-Data-from-Phase-2a-INTEGRIS-PSC-Clinical-Trial-of-Bexotegrast-in-Patients-with-Primary-Sclerosing-Cholangitis.html
https://www.globenewswire.com/news-release/2023/08/09/2721574/0/en/Pliant-Therapeutics-Announces-Initiation-of-BEACON-IPF-a-Phase-2b-Clinical-Trial-of-Bexotegrast-in-Idiopathic-Pulmonary-Fibrosis.html
https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-presents-data-its-bexotegrast-program-0
https://www.globenewswire.com/news-release/2023/06/23/2693609/0/en/Pliant-Therapeutics-Presents-Data-from-its-Bexotegrast-Program-at-the-European-Association-for-the-Study-of-the-Liver-EASL-International-Liver-Congress.html
https://www.globenewswire.com/news-release/2023/04/30/2658013/0/en/Pliant-Therapeutics-Announces-Positive-Long-Term-Data-from-the-INTEGRIS-IPF-Phase-2a-Trial-Demonstrating-Bexotegrast-was-Well-Tolerated-at-320-mg-with-Durable-Improvement-Shown-in-.html
https://www.clinicaltrialsarena.com/news/pliant-therapeutics-bexotegrast-trial/
https://www.globenewswire.com/news-release/2023/03/13/2625680/0/en/Pliant-Therapeutics-Announces-Positive-DSMB-Safety-Review-and-Initiation-of-Enrollment-of-Phase-2a-Trial-of-Bexotegrast-PLN-74809-at-320-mg-Dose-in-Primary-Sclerosing-Cholangitis.html
https://www.globenewswire.com/news-release/2023/01/22/2592836/0/en/Pliant-Therapeutics-Announces-Positive-Data-from-the-INTEGRIS-IPF-Phase-2a-Trial-Demonstrating-Bexotegrast-320-mg-was-Well-Tolerated-and-Achieved-Statistically-Significant-FVC-Incr.html
https://www.globenewswire.com/news-release/2022/12/15/2574526/0/en/Pliant-Therapeutics-Receives-Orphan-Designation-from-the-European-Medicines-Agency-for-Bexotegrast-PLN-74809-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html